Work

Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials

Year: 2016

Type: article

Abstract: Case presentations Case 1After induction using 713 cytarabine-idarubicin, a 64-year-old man with cytogenetically normal acute myeloid leukemia (AML) without FLT3-ITD, NPM1, and CEBPA mutations achieved a morphologic complete remission (CR).The patient was not interested in allogeneic hematopoietic cell transplantation (allo-HCT) at that time and underwent 3 cycles of consolidation with high-dose cytarabine 3 g/m 2 for 6 doses per cycle.Would maintenance therapy after completion of high-dose cytarabine be of any value in prolonging survival?Case 2 A 41-year-old otherwise healthy woman was diagnosed with normal karyotype AML and an FLT3-ITD mutation.After 713 induction, she achieved a morphologic CR.Treatment was consolidated with a myeloablative T-replete allo-HCT from her HLA-matched brother.Her early posttransplant course was uneventful, and full donor chimerism was documented on her day 130 bone marrow examination with no evidence of morphologic or cytogenetic relapse and no graft-versus-host disease.Should maintenance therapy be recommended to reduce the risk of relapse and improve posttransplant outcomes?

Source: Blood

DOI: 10.1182/blood-2016-03-674127

Authors: Armin Rashidi, Roland B. Walter, Martin S. Tallman, Frederick R. Appelbaum, John F. DiPersio

Institutions: Washington University in St. Louis, University of Washington, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Institute of Clinical and Translational Sciences, National Institutes of Health, National Cancer Institute, National Center for Advancing Translational Sciences